Companies › Fidia Farmaceutici
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) Paclitaxel (microtubule stabilizer) formulated with hyaluronic acid for intravesical deliv | Tubulin | Phase 3 | Bladder Carcinoma in Situ (CIS) | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05024773 | ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | Phase 3 | Bladder Carcinoma in Situ (CIS) | Oncology | May 2028 |
Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen GSK Beijing Biostar Pharmaceuticals Urotronic Ambrx
Beijing Biostar Pharmaceuticals Verity Pharmaceuticals SecuraBio Sumitomo Pharma Switzerland Eleison Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.